METTL14 and colorectal cancer: IGF2BP3 functions as an m6A reader to stabilize and enhance translation of EGFR mRNA through collaboration with METTL14, thereby activating EGFR signaling and conferring therapeutic resistance to cetuximab in colorectal cancer [260].